Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Increased Earnings Estimates Seen for ProQR Therapeutics (PRQR): Can It Move Higher?

ProQR Therapeutics N.V. PRQR is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PRQR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that ProQR Therapeutics could be a solid choice for investors.

Current Quarter Estimates for PRQR

In the past 30 days, no estimates have gone higher for ProQR Therapeutics. However, the trend has been pretty favorable, with estimates narrowing from a loss of 49 cents a share 30 days ago, to a loss of 42 today, a move of 14.3%.

Current Year Estimates for PRQR    

Meanwhile, ProQR Therapeutics’s current year consensus estimate figures have also seen a boost in the past month, narrowing from a loss of $2.20 per share 30 days ago to a loss of $1.86 per share today, an increase of 15.5%.

Bottom Line

The stock has also started to move higher lately, adding 37.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PROQR THERAP (PRQR): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research